Primers/Probes Sequences and Concentration Used in Each Pool for the <i>S</i>. <i>pneumoniae</i> Serotype Identification and Quantification Assay.

<p>Primers/Probes Sequences and Concentration Used in Each Pool for the <i>S</i>. <i>pneumoniae</i> Serotype Identification and Quantification Assay.</p

<i>S</i>. <i>pneumoniae</i> serotypes distribution determined by the 40 <i>S</i>. <i>pneumoniae</i> serotype real-time PCR typing assay (40-PCR).

<p>(A) in NP samples (n = 562) of patients from Cambodia (n = 149), France (n = 45), South Africa (n = 227), Mali (n = 86) and Brazil (n = 55), (B) in WB samples (n = 102) of patients from France (n = 5), Mali (n = 16) and South Africa (n = 81). Each column represents the cumulative number of patients for a given serotype.</p

Serotype-Dependent Detection Limits and Linear Equation Values.

<p>Serotype-Dependent Detection Limits and Linear Equation Values.</p

Pneumococcal load distribution in NP samples from the South African cohort.

<p>Comparison between invasive (present in both NP and WB samples of the same patient; n = 36) and non-invasive serotypes (present in NP samples only; n = 145). Each plot represents a sample. The bold bars indicate the mean bacterial concentration for each group (Student's <i>t</i>-test, <i>P</i><0.001).</p

Efavirenz plasma concentrations at sampling time.

<p>Efavirenz plasma concentrations at sampling time.</p

Univariate and multivariate analysis of risk factors associated with efavirenz plasma concentration below 1,000/mL.

<p>Percentiles are gender-specific. IRIS: paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome.</p><p>Sampling times were: 2 weeks after ART initiation, 6 weeks after ART initiation, at 22 weeks of follow-up, and at 50 weeks of follow-up. See text for details.</p

Study population.

<p>Study population.</p

Efavirenz concentrations at week 22 and week 50 in patients whose efavirenz concentrations >4,000 ng/mL.

<p>Efavirenz concentrations at week 22 and week 50 in patients whose efavirenz concentrations >4,000 ng/mL.</p

Distribution of efavirenz plasma concentrations according to the therapeutic range at each sampling time.

<p>Distribution of efavirenz plasma concentrations according to the therapeutic range at each sampling time.</p

Characteristics of the 540 patients at ART initiation.

<p>ART: Antiretroviral Treatment; IQR: interquartile range; AST: aspartate aminotransferase; ALT: alanine aminotransferase.</p